Clinical studies of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) enroll patients with a very wide spectrum of disease, in part, related to the patient and/or host, the causative pathogen, and the severity of the pulmonary disease, severity of illness, and other comorbidities. Studies have identified the presence of some baseline variables (eg, Acute Physiologic Assessment and Chronic Health Evaluation II score р20 or absence of comorbidities) as independent predictors of survival. Incorporation of severity scoring and risk adjustment in clinical trials of HAP and VAP may be a significant advancement because it has been noted that all-cause mortality varies widely on the basis of a number of these factors. In this article, we review the use of severity scoring and risk stratification factors, including time of onset, severity of disease, scoring systems, underlying disease and comorbidities, and effects of prior antibiotic therapy (including impact on treatment effect) in clinical trials of HAP and/or VAP.
DEFINITIONS
VAP is defined as pneumonia developing in a patient who has received mechanical ventilation for у48 h [1] . HAP is defined as pneumonia occurring у48 h after hospital admission and not incubating at the time of admission. The newer category of health care-associated pneumonia is defined as pneumonia occurring in patients with у1 of several risk factors for MDR bacteria as the cause of the pulmonary infection (Table 1 ) [1, 2] . Patients with HAP and health care-associated pneumonia may have severe pneumonia requiring mechanical ventilation and admission to the intensive care unit (ICU). There are significant mortality differences noted among these specific pneumonia categories (Figure 1 ) [3] .
TIME OF ONSET: EARLY VS LATE
VAP probability is directly related to duration (days) of mechanical ventilation and intubation ( Figure 2 ) [4] . The American Thoracic Society and Infectious Diseases Society of America guidelines classify HAP and VAP on the basis of time of onset. For HAP, the onset is defined in reference to the time of hospitalization: early-onset HAP is pneumonia diagnosed 2-5 days after hospital- Health care-associated pneumonia Pneumonia in patients with у1 of the following risk factors for infection due to MDR bacteria: (1) hospitalization for у2 days in an acute care facility within 90 days before infection; (2) residence in a nursing home or long-term care facility; (3) antibiotic therapy, chemotherapy, or wound care within 30 days before current infection; (4) hemodialysis treatment at a hospital or clinic; (5) home infusion therapy or home wound care; or (6) family member with infection due to MDR bacteria Community-acquired pneumonia Pneumonia occurring outside the hospital in patients who do not meet the criteria for health care-associated pneumonia NOTE. Data are from [1] . MDR, multidrug-resistant.
ization; late-onset HAP is pneumonia diagnosed у5 days after hospitalization. For VAP, the onset is defined in reference to the time of intubation: early-onset VAP is pneumonia diagnosed 48-72 h (2-4 days) after intubation; late-onset VAP is pneumonia diagnosed у5 days after intubation (Table 2 ) [1] . In the past, causative pathogens for HAP and VAP varied with respect to the time of disease onset relative to the time of hospital admission and/or intubation. The microbiology of early HAP and/or VAP was antibiotic-susceptible organisms, the most common of which were Streptococcus pneumoniae, Haemophilus influenzae, methicillin-susceptible Staphylococcus aureus, and antimicrobial-susceptible gram-negative bacilli (Escherichia coli, Klebsiella species, Proteus species, and Enterobacter species). In contrast, late HAP and/or VAP microbiology included methicillin-resistant S. aureus and MDR gram-negative bacilli (Pseudomonas aeruginosa, Acinetobacter species, Enterobacter species, and extended-spectrum b-lactamase-positive strains).
It has been documented that the attributable mortality associated with VAP applies particularly to patients with lateonset VAP, for which there is an increased likelihood that the causative pathogen is MDR. Both duration of mechanical ventilation and previous antibiotic exposure are significant risk factors for MDR pathogens as the etiology of VAP (Table 3 ) [5] .
SEVERITY OF DISEASE

Risk stratification in community-acquired pneumonia (CAP).
Risk stratification for CAP has been accomplished using 2 scoring systems: the CURB-65 score (5 variables: confusion, urea nitrogen level, respiratory rate, blood pressure, age у65 years) and the pneumonia-specific severity index (PSI) (Tables 4-6), which was derived and validated as part of the Pneumonia Patient Outcomes Research Team prospective cohort study. In the PSI clinical prediction rule, clinically significant risk factors are added together to produce a PSI score, which has been correlated with need for hospital admission and treatment and mortality risk (Tables 4 and 5 ) [6] . In the CURB-65 score, the 5 variables are compiled, and increasing scores are associated with increased mortality (Table 6 ) [7] [8] [9] [10] . These uniform risk stratification tools for CAP identify patients at higher risk of mortality. From a research perspective, risk stratification can be used to select appropriate patient subgroups for clinical trials and to provide severity-adjusted outcomes comparisons. Neither CURB-65 nor PSI scores have been validated for use in HAP and/or VAP but provide a potential framework for development of a similar score to be used in future HAP and VAP clinical trials.
Risk stratification in HAP and/or VAP: Clinical Pulmonary Infection Score (CPIS). Currently, no such similar diseasebased scoring system is in use for HAP or VAP. Therefore, in clinical trials of HAP and/or VAP, the enrolled patient cohort is very heterogenous, with variable mortality risk that may not be fully controlled for in randomization. Other surrogate measures of severity of disease are frequently used in HAP and/or VAP clinical trials, such as the Acute Physiology and Chronic Health Evaluation score (APACHE II, APACHE III, and APACHE IV) as a measure of overall severity of illness and Sequential Organ Failure Assessment (SOFA) score as a measure of organ dysfunction and failure (see Scoring Systems below).
The CPIS has been used to aid in the diagnosis of VAP (Table  7) . A total score 16 suggests VAP. Initially, the CPIS was validated in only 40 quantitative cultures of bronchoalveolar lavage (BAL) fluid specimens from 28 patients. It has been identified that the most sensitive component of this score is improvement in oxygenation. In a randomized trial, the CPIS was used as operational criteria for decision making regarding antibiotic therapy in VAP [11] . In 2000, the CPIS was modified by Singh et al (Table 8 ) [12] . A study using short-course empirical antibiotic therapy for patients with pulmonary infiltrates in the ICU used this modified CPIS at baseline, assessed on the basis of the first 5 variables. The CPIS at 72 h was calculated on the basis of all 7 variables and took into consideration the progression of the infiltrate and culture results of the tracheal aspirate specimen. A CPIS 16 at baseline or at 72 h was considered to be suggestive of pneumonia.
The diagnostic accuracy of the CPIS was assessed in 79 patients with suspected VAP, incorporating the Gram stain or culture results of BAL fluid by adding 2 more points if they were positive [13] . It was identified that the CPIS had low diagnostic accuracy; however, incorporating Gram stain results into the CPIS increased the diagnostic accuracy (sensitivity and specificity of 85% and 49% vs 78% and 56%, respectively). Another study compared the CPIS with quantitative BAL culture results in 99 patients with suspected VAP, using growth of 1 colony-forming units (cfu)/mL in BAL fluid as a cutoff 4 1 ϫ 10 for VAP diagnosis. In addition, the CPIS was calculated by 2 different intensivists to determine interobserver variability. When using a CPIS 15 as a diagnostic cutoff, the sensitivity of the score was 83% and its specificity was 17%; the area under the receiver-operating characteristic curve (ROC AUC) was 0.55. Furthermore, the level of agreement for prospectively measured CPIS scores (р6 and 1 6) was poor (k, 0.16). Compared with quantitative cultures of BAL fluid samples, the CPIS has a low sensitivity and specificity for diagnosing VAP, with considerable interobserver variability [14] . In this study, of the individual CPIS variables, only a positive result of microbiological culture of a tracheal aspirate specimen was significantly associated with VAP (odds ratio ). P p .007
Most recently, the value of pretest probability and modified CPIS to diagnose VAP was assessed by the Canadian Critical Care Trials Group [15] . In 740 patients enrolled in a multicenter randomized trial, intensivists prospectively rated the pretest probability of VAP as low, moderate, or high on the basis of clinical judgment. The modified CPIS was calculated without considering culture results. VAP diagnosis was determined by 2 adjudicators using standardized definitions. The ROC AUC for the modified CPIS was not significant (0.47; 95% CI, 0.42-0.53), meaning that no CPIS threshold was clinically useful. The CPIS was of limited use in the diagnosis of VAP in this and many other studies and should not be used as a risk stratification tool in HAP and/or VAP studies.
Additional studies have shown the futility of CPIS use in trauma and burn patients. A study involving 158 trauma patients revealed that the mean CPIS was 6.9 in patients with VAP (defined as у105 cfu/mL in BAL fluid), compared with a mean CPIS of 6.8 in patients with systemic inflammatory response syndrome. The CPIS was unable to differentiate VAP from systemic inflammatory response syndrome in trauma patients ( Figure 3 ) [16] . A study involving burn patients compared the accuracy of the CPIS with that of quantitative BAL fluid culture and reported a mean CPIS of 5.5 for patients with positive BAL fluid specimens, compared with a mean CPIS of 5.7 for patients with negative BAL fluid specimens. CPIS sensitivity was 30%, specificity was 80%, positive predictive value was 70%, and negative predictive value was 50% [17] . The poor performance of the CPIS in trauma and burn patients is problematic, because VAP rates are currently highest in trauma, burn, and surgical ICUs (Table 9 ) [18] [19] [20] .
Despite the poor performance of CPIS in the diagnosis of VAP, the clinical practice guidelines for HAP and VAP in adults from Canada, prepared jointly by the Association of Medical Microbiology and Infectious Disease Canada and the Canadian Thoracic Society [21] , recommend the following: (1) the CPIS should be calculated to improve sensitivity and specificity for the diagnosis of HAP and VAP, (2) a low CPIS may allow careful observation of the patient without antibiotics, and (3) by the third day of calculating the CPIS, a score !6 may allow early discontinuation of antibiotics. Although this recommendation may be used in clinical practice in the care of patients with HAP and/or VAP, the data from multiple aforementioned studies do not support the use of the CPIS as a risk stratification tool in HAP and VAP clinical trials.
Risk stratification in HAP and/or VAP: clinical characteristics. It has also been documented that specific clinical characteristics correlate with eventual outcomes of VAP. Among 563 patients with confirmed VAP from a large, randomized, controlled trial comparing different modalities for the diagnosis and treatment of VAP, risk factors associated with clinical failure were identified [22] . In multivariate analysis, 4 factors were independently associated with clinical failure: older age, duration of mechanical ventilation before enrollment, presence of neurologic disease at admission, and failure of the ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen to improve by day 3. Integration of these clinical characteristics into a severity score for VAP could be considered as a strategy in future VAP clinical trials.
Risk stratification in HAP and/or VAP: severity of pneumonia and pulmonary disease. A number of features related to the severity of the pneumonia have been documented to impact on the outcome of HAP and/or VAP. Logistic regression analysis of 2 large clinical trials involving patients with suspected gram-positive nosocomial pneumonia determined the effect of treatment and other baseline variables on outcomes [23, 24] . Significant predictors of clinical cure in all patients with nosocomial pneumonia were an APACHE II score р20 (OR, 2.9; 95% CI, 1.9-4.7;
), single-lobe pneumonia P ! .01 (OR, 1.7; 95% CI, 1.3-2.4; ), absence of VAP (OR, 2.1; P ! .01 95% CI, 1.5-2.9;
), and absence of oncologic (OR, 2.3; P ! .01 95% CI, 1.3-4.0;
) and renal comorbidities (OR, 2.3; P ! .01 Pleural effusion +10 NOTE.
Step 1: if a patient is !51 years of age and has no coexisting illnesses or no abnormal physical examination findings, the risk class is 1. Otherwise, assess the characteristics in the table and add the score to determine the risk class.
Step 2: assess risk factors and assign points. Adapted with permission. ᮊ1997 Massachusetts Medical Society. All rights reserved. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336(4):243-50 [6] 95% CI, 1.4-3.8;
). Significant predictors of clinical cure P ! .01 in both the S. aureus and MRSA subsets were single-lobe pneumonia, absence of VAP, and absence of oncologic and renal comorbidities. Adjustment for differences in these baseline variables could be used as a strategy in future clinical trials of HAP and VAP.
The presence of other issues related to severity of disease (ie, necrotizing vs nonnecrotizing pneumonia and underlying pulmonary diseases) clearly has an impact on outcome in patients with HAP or VAP; however, these conditions are not currently controlled for in clinical pneumonia trials. CT imaging for patients with HAP or VAP has provided greater detail regarding severity of pneumonia and, in particular, is very useful in determining whether necrotizing pneumonia is present. CT imaging can define a more specific pattern of abnormalities than can conventional chest radiograph in patients with necrotizing pneumonia and allows an earlier diagnosis of this rapidly progressive condition [25] . High-resolution CT imaging has significant advantages of superior contrast resolution and crosssectional display and has also been shown to be more sensitive than plain radiography in the early detection of pulmonary infections [26] [27] [28] .
Of importance, an infiltrate on chest radiograph is nonspecific for the diagnosis of posttraumatic pneumonia, and only ∼50% of trauma patients with this finding have pneumonia [29] . This is, in part, related to the common findings of thoracic trauma, including pulmonary contusions, aspiration, and atelectasis, in this trauma patient population. Improved diagnostic imaging studies, such as CT rather than chest radiographs, in HAP and/or VAP clinical trials may provide greater resolution of the severity of pneumonia, which has important implications for patient outcome. Most trauma ICUs use quantitative BAL fluid cultures as specific diagnostic criteria for HAP and VAP in trauma patients [30] . The use of quantitative assessment of deep tracheal aspirate specimens for the diagnosis of VAP in trauma patients was associated with a high rate of overdiagnosis of VAP and unnecessary antibiotic administration (31% at a cutoff of 1 cfu/mL; 42% at cutoff of cfu/mL) 5 4 1 ϫ 10 1 ϫ 10 and is not recommended [31] .
Risk stratification in HAP and/or VAP: patient type categories. The first question to address is whether HAP and VAP should be included in the same clinical trial design, because such a trial would enroll a very heterogeneous patient population with variable outcomes and a wide mortality range. Clinical trials that enroll only patients with VAP comprise a more homogenous patient cohort, because all patients are intubated and receive mechanical ventilation in an ICU. In contrast, clinical trials that enroll both patients with HAP and patients with VAP include some patients who are not intubated and not in an ICU. The overall reported mortality rate in VAP clinical trials was 20.3% in a recent systematic review and meta-analysis of randomized trials (41 trials with 7015 patients) of empirical antibiotic therapy for suspected VAP [32] . Alternatively, inclusion and enrollment of only patients with HAP or VAP who require mechanical ventilation and ICU care would be another strategy to achieve a more homogeneous patient population.
There are a number of different patient populations that are at risk for HAP and/or VAP, including (1) medical patients, (2) surgical nontrauma patients, and (3) ) [33] . P p .05 These patient populations are quite different, and risk stratification for these patient populations is also different. In trauma patients, we have standardized severity of injury scoring by Injury Severity Score, and a higher Injury Severity Score is [12] . a ARDS defined as PaO 2 :FiO 2 р200, pulmonary arterial wedge pressure р18 mm Hg, and acute bilateral infiltrates.
associated with higher mortality risk [34] . For trauma patients enrolled in HAP and/or VAP trials, it is important to riskstratify them by overall Injury Severity Score and specifically stratify by degree of lung injury by thoracic abbreviated injury scale [35] . The presence of pulmonary contusion and abbreviated injury scale of 14 for thorax were significant independent predictors of pneumonia after injury [36] . Patients with traumatic brain injury are at very high risk of VAP, and these trauma patients should be stratified by Glasgow Coma Scale at admission and head abbreviated injury scale to adjust for the severity of their traumatic brain injury, because that directly impacts on their survival. In addition to risk stratification by severity of specific injuries in trauma patients, risk stratification by severity of pneumonia is also required in clinical trials. Neither of these are currently required in the conduct of HAP and/ or VAP clinical trials but would be a significant advance in experimental design.
Other clinical trials have stratified randomization and enrollment according to 3 mutually exclusive admission patient groups, including trauma, surgical nontrauma, and medical nontrauma patients, and have identified specific outcome differences [37, 38] . This method (ie, separate randomization of the 3 patient groups at baseline) should be seriously considered in future HAP and/or VAP clinical trials.
SCORING SYSTEMS
Severity of illness.
There is a need to limit the sources of heterogeneity in HAP and/or VAP clinical trials by a better definition of the target population; by a better estimation of NOTE. Data are from National Nosocomial Infections Surveillance System and National Healthcare Safety Network reports [18] [19] [20] .
outcomes, including mortality; and by controlling for cointerventions [39, 40] . Mortality in the ICU is significantly affected by patient demographic characteristics, comorbidities, and severity of illness, and risk-prediction models have been developed to adjust for these factors. A number of different prognostic scoring systems are used in critical care, including the Therapeutic Intervention Scoring System, the Mortality Predictor Model, the Simplified Acute Physiology Score, and the APACHE II, APACHE III, and APACHE IV scores [41] . These models differ substantively in the number and type of variables used to assess mortality risk [42, 43] .
These scoring systems are important in the conduct of clinical trials, and the APACHE score at hospital admission is most frequently used in ICU clinical trials for stratification of baseline clinical characteristics. Some clinical trials have documented differing treatment effects between patients with lower and higher APACHE II scores, documenting the importance of this stratification method [44] . Significant variation in ICU riskadjusted mortality has been identified [45] .
The value of the APACHE II, SOFA, and CPIS scores in the prediction of mortality during VAP episodes in pulmonary patients was assessed. Discrimination was excellent for the APACHE II score (ROC AUC, 0.81;
) and acceptable P p .001 for the SOFA score (ROC AUC, 0.71;
). Of the 3 scores P p .005 only an APACHE II score 116 was an independent predictor of mortality (OR, 5; 95% CI, 1.3-18; ) in the logistic P p .019 regression analysis. These results suggest that the APACHE II score determined at the time of VAP diagnosis may be useful in mortality prediction [46] . It has also been documented that the APACHE II score (ROC, 0.805; 95% CI, 0.743-0.866) outperformed the CURB65 (ROC, 0.634; 95% CI, 0.541-0.727) and CRB65 (ROC, 0.643; 95% CI, 0.546-0.739) scores for initial prognostic assessment in patients with MRSA pneumonia ( ), with an all-cause in-hospital mortality rate of 20.2% n p 218 in the cohort [47] .
On the basis of the aforementioned studies, a scoring system for severity of illness should be included in all future HAP and/ or VAP clinical trials as either a criterion for study entry or in a stratification scheme, and APACHE II or III scores have emerged as the most common tools. The recent VAP study comparing doripenem with imipenem excluded patients with APACHE II scores !8 or 129 and excluded unstable patients with acute respiratory distress syndrome, septic shock, severe renal disease or dialysis, or immediate life-threatening illness [48] . This led to a substantially lower 28-day all-cause mortality rate of 10.8% in the doripenem arm and 9.5% in the imipenem arm, compared with prior reported mortality rates of 20% in VAP clinical trials [21] .
Organ dysfunction and failure. Organ dysfunction and organ failure scoring systems are also used to stratify ICU patients by severity of illness and in clinical trials. By using data from one of the largest multicenter prospective trials on VAP (PNEUMA Trial [49] ) in which detailed information on patient characteristics was available before VAP onset and was thereafter assessed frequently until day 28, it was confirmed that organ dysfunction and/or failure (measured by SOFA or Organ Dysfunction and/or Infection scores) were independent predictors of VAP recurrence and mortality [50] . In addition, acute refractory multiple organ dysfunction syndrome was the most frequent cause of death in the ICU (47%) in a study involving 3700 patients admitted to an adult ICU [51] . Multiple organ dysfunction syndrome (MODS) was more common than single-organ failure or unexpected cardiac arrest as a cause of death in these ICU patients. Furthermore, 60% of patients with sepsis had organ failure at ICU admission [52] . The modified MODS score ( Figure 4 ) describes and quantifies organ-specific physiology and includes 6 components of MODS (cardiovascular, respiratory, renal, central nervous system, hepatic, and hematologic) measured at admission to the ICU and during an ICU stay [53] . Similarly, the SOFA score is frequently used to describe organ dysfunction or failure in ICU patients ( Figure 5 ) [54, 55] . Both of these organ dysfunction scores (SOFA and MODS) have a significant correlation with mortality and should be included as stratification factors to ensure baseline comparability of the study cohorts in the conduct of all HAP and/ or VAP clinical trials.
Sepsis and infection: predisposition, insult, response, and organ dysfunction (PIRO). A single scoring system that merged both severity and/or acuity of illness and organ dysfunction could be potentially more useful in HAP and/or VAP clinical trials than could separate scoring systems for each. The 2001 International Sepsis Definitions Conference first proposed the PIRO concept for staging sepsis [56] . This was proposed as a clinically useful staging system that stratifies patients with a disease by both baseline risk of an adverse outcome and potential of response to therapy. Such systems are widely used in clinical medicine, such as the disease stratification system in oncology, the TNM system, which classifies malignant tumors on the basis of descriptors of the primary tumor, metastases to regional lymph nodes, and distant metastases. Recently, an initial version of the PIRO staging model for risk stratification in severe sepsis was developed ( Figure 6 ) with classification and regression trees used to derive the scoring system and was validated using 2 large global databases of patients with severe sepsis (840 and 10,610 patients) [57] . Increasing PIRO score was associated with increased hospital mortality in patients with sepsis.
No score is consistently currently used to assess severity and stratify mortality risk in VAP, but specific independent predictors of increased mortality have been identified. It is well known that the presence of bacteremia in patients with VAP is associated with increased mortality. In a recent study comparing doripenem with imipenem in patients with VAP, the bacteremia rate at baseline was 10.3% in the doripenem cohort and 9.0% in the imipenem cohort [37] . In a study of 199 microbiologically confirmed VAP episodes, bacteremic VAP was confirmed to be associated with increased mortality with use of multivariate analysis (hazard ratio for death, 2.55; 95% CI, 1.25-5.23;
) [58] . Severity of lung injury, measured as the P p .01 ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, was also identified as an independent predictor of infection recurrence or death in prior VAP studies [59] .
The VAP PIRO score was subsequently developed as a concept for ICU mortality risk stratification of patients with VAP [60] . A prospective, observational cohort study was performed that included 441 patients with VAP in 3 multidisciplinary ICUs. Multivariate logistic regression was performed to identify variables independently associated with ICU mortality. Results were then converted into a 4-variable score (Tables 10 and 11) based on the PIRO concept for ICU mortality risk stratification in patients with VAP, including (1) comorbidities (chronic obstructive pulmonary disease, immunocompromised state, heart failure, cirrhosis, or chronic renal failure), (2) bacteremia, (3) systolic blood pressure !90 mm Hg, and (4) acute respiratory distress syndrome.
This simple, 4-variable VAP PIRO score was obtained at VAP onset. Mortality varied significantly according to VAP PIRO score ( ). On the basis of observed mortality for each P ! .001 VAP PIRO score, patients were stratified into 3 levels of risk: (1) mild (0-1 point), (2) high (2 points), and (3) very high (3-4 points). The VAP PIRO score was associated with higher risk of death in Cox regression analysis among the group at high risk (hazard ratio, 2.14; 95% CI, 1.19-3.86) and among the group at very high risk (hazard ratio, 4.63; 95% CI, 2.68-7.99). Moreover, medical resource use after VAP diagnosis was higher among patients at the high-risk and very-high-risk levels than among patients at mild risk, as evaluated using mean ‫ע(‬ SD ). The P ! .001 authors [60] concluded that the VAP PIRO score is a simple, practical clinical tool for predicting ICU mortality and health care resource use that is likely to assist clinicians in determining VAP severity.
There were a number of major study limitations to the VAP PIRO score, however, including the fact that only ICU mortality was considered, no measure of severity of shock was included, a low number of patients with an invasive approach to VAP diagnosis were included in the study, and the study was multicenter, at 3 ICUs in Spain. This score must be further validated but could potentially be considered for use in risk stratification in HAP and/or VAP clinical trials in the future.
UNDERLYING DISEASE AND COMORBIDITIES
A number of underlying chronic diseases and comorbidities impact on the eventual outcome in patients with HAP and VAP. These include cancer; chronic obstructive pulmonary disease and other chronic pulmonary diseases; chronic cardiac disease, including heart failure; and renal insufficiency and failure. It has been documented that resolution of VAP depends not only on the accuracy of the microbial diagnosis and correct antimicrobial treatment, but also on the presence of comorbidities, the response of the host to the infection, and other organ dysfunction or failures [61] .
As described above, the VAP PIRO score includes presence of comorbidities (chronic obstructive pulmonary disease, immunocompromised state, heart failure, cirrhosis, or chronic [58] renal failure) as 1 of the 4 components identified to be independently associated with increased mortality. The VAP PIRO score could therefore serve to quantify relevant comorbidities in future HAP and/or VAP clinical trials.
EFFECT OF PRIOR ANTIBIOTICS (INCLUDING IMPACT ON TREATMENT EFFICACY)
Risk factors for infection due to MDR pathogens include (1) antimicrobial therapy in the preceding 90 days, (2) high frequency of antibiotic resistance in the community or the specific hospital unit or ICU, and (3) immunosuppressive disease and/ or therapy. Specific risk factors for infection due to MDR pathogens are also present in patients who have risk factors for health care-associated pneumonia, as described by the American Thoracic Society and Infectious Diseases Society of America guidelines, including (1) hospitalization for у2 days in the preceding 90 days, (2) residence in a nursing home or extendedcare facility, (3) receipt of home infusion therapy (including antibiotics), (4) receipt of long-term dialysis within 30 days, (5) home wound care, and (6) family member with infection due to an MDR pathogen.
The determinants and impact of antibiotic resistance in pathogens causing VAP was recently reported [62] . In this study of 192 episodes of VAP, MDR pathogens were involved in 52 cases (in 27% of the study cohort). ), and septic shock at admission to the ICU (stan-P p .03 dardized hazard ratio, 1.86; 95% CI, 1.03-3.35;
), but P p .03 not MDR etiology of VAP, were independent predictors of mortality. Of interest, this study documented that the risk of MDR pathogens causing VAP was mainly determined by comorbidity and prior exposure to 12 antibiotics. The increased mortality associated with VAP due to MDR pathogens, compared with VAP due to non-MDR pathogens, was explained by more severe comorbidity and organ failure before VAP.
CONCLUSION
Clinical studies of HAP and VAP enroll patients with a very wide spectrum of disease, related, in part, to the patient and/ or host, the causative pathogen, the severity of the pulmonary disease and other illness, and presence of comorbidities, with resultant wide variability in outcomes. Future HAP and/or VAP clinical trials should include only patients requiring mechanical ventilation and ICU care to avoid heterogeneity of the study population. The development of disease-specific (pneumonia) severity scoring and risk adjustment tools for use in clinical trials of HAP and VAP would represent a significant advancement in clinical trial design. A number of variables that have been identified as independent predictors of outcome of pneumonia must be considered in this disease-specific risk stratification, including severity of disease (necrotizing vs nonnecrotizing, number of lobes affected, presence of acute respiratory distress syndrome, bacteremia, severe sepsis, or septic shock), severity of illness (APACHE score), presence of organ dysfunction or failure (MODS or SOFA score), underlying diseases and comorbidities, and specific causative pathogens (MDR pathogens or not). The VAP PIRO score is a potentially useful concept that must be further validated in clinical trials before widespread use. Finally, stratification of randomization and enrollment according to 3 mutually exclusive admission groups, including trauma, surgical nontrauma, and medical nontrauma patients, should be seriously considered in future HAP and/or VAP clinical trials, because clinical outcomes have been documented to differ in these patient populations.
